These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 8933995)
1. Alniditan in the acute treatment of migraine attacks: a subcutaneous dose-finding study. Subcutaneous Alniditan Study Group. Goldstein J; Dahlöf CG; Diener HC; Olesen J; Schellens R; Senard JM; Simard D; Steiner TJ Cephalalgia; 1996 Nov; 16(7):497-502. PubMed ID: 8933995 [TBL] [Abstract][Full Text] [Related]
2. The efficacy and safety of sc alniditan vs. sc sumatriptan in the acute treatment of migraine: a randomized, double-blind, placebo-controlled trial. Diener HC; Tfelt-Hansen P; de Beukelaar F; Ferrari MD; Olesen J; Dahlöf C; Mathew N; Cephalalgia; 2001 Jul; 21(6):672-9. PubMed ID: 11531899 [TBL] [Abstract][Full Text] [Related]
3. Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. The Diclofenac-K/Sumatriptan Migraine Study Group. Cephalalgia; 1999 May; 19(4):232-40. PubMed ID: 10376168 [TBL] [Abstract][Full Text] [Related]
4. Treatment of migraine attacks with intranasal alniditan: an open study. Diener HC; Louis P; Schellens R; De Beukelaar F; Cephalalgia; 2001 Mar; 21(2):140-4. PubMed ID: 11422097 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic profile of alniditan nasal spray during and outside migraine attacks. Roon KI; Soons PA; Uitendaal MP; de Beukelaar F; Ferrari MD Br J Clin Pharmacol; 1999 Mar; 47(3):285-90. PubMed ID: 10215753 [TBL] [Abstract][Full Text] [Related]
6. Sumatriptan. An updated review of its use in migraine. Perry CM; Markham A Drugs; 1998 Jun; 55(6):889-922. PubMed ID: 9617601 [TBL] [Abstract][Full Text] [Related]
7. Migraine and cluster headache--their management with sumatriptan: a critical review of the current clinical experience. Wilkinson M; Pfaffenrath V; Schoenen J; Diener HC; Steiner TJ Cephalalgia; 1995 Oct; 15(5):337-57. PubMed ID: 8536293 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan. Pfaffenrath V; Cunin G; Sjonell G; Prendergast S Headache; 1998 Mar; 38(3):184-90. PubMed ID: 9563208 [TBL] [Abstract][Full Text] [Related]
9. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group. Rapoport AM; Ramadan NM; Adelman JU; Mathew NT; Elkind AH; Kudrow DB; Earl NL Neurology; 1997 Nov; 49(5):1210-8. PubMed ID: 9371896 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of naratriptan tablets in the acute treatment of migraine: a dose-ranging study. Naratriptan S2WB2004 Study Group. Havanka H; Dahlöf C; Pop PH; Diener HC; Winter P; Whitehouse H; Hassani H Clin Ther; 2000 Aug; 22(8):970-80. PubMed ID: 10972633 [TBL] [Abstract][Full Text] [Related]
11. Two replicate randomized, double-blind, placebo-controlled trials of the time to onset of pain relief in the acute treatment of migraine with a fast-disintegrating/rapid-release formulation of sumatriptan tablets. Sheftell FD; Dahlöf CG; Brandes JL; Agosti R; Jones MW; Barrett PS Clin Ther; 2005 Apr; 27(4):407-17. PubMed ID: 15922814 [TBL] [Abstract][Full Text] [Related]
12. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. Brandes JL; Kudrow D; Stark SR; O'Carroll CP; Adelman JU; O'Donnell FJ; Alexander WJ; Spruill SE; Barrett PS; Lener SE JAMA; 2007 Apr; 297(13):1443-54. PubMed ID: 17405970 [TBL] [Abstract][Full Text] [Related]
13. Open-labeled long-term study of the efficacy, safety, and tolerability of subcutaneous sumatriptan in acute migraine treatment. Göbel H; Heinze A; Stolze H; Heinze-Kuhn K; Lindner V Cephalalgia; 1999 Sep; 19(7):676-83; discussion 626. PubMed ID: 10524662 [TBL] [Abstract][Full Text] [Related]
14. A double-blind placebo-controlled study assessing the efficacy and tolerability of 50 mg sumatriptan tablets in the acute treatment of migraine. Sumatriptan Tablets S2CM07 Study Group. Savani N; Brautaset NJ; Reunanen M; Szirmai I; Ashford EA; Hassani H; Saiers J Int J Clin Pract Suppl; 1999 Aug; 105():7-15. PubMed ID: 10692717 [TBL] [Abstract][Full Text] [Related]
15. Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison. Diener HC; Jansen JP; Reches A; Pascual J; Pitei D; Steiner TJ; Eur Neurol; 2002; 47(2):99-107. PubMed ID: 11844898 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of sumatriptan tablets in migraineurs self-described or physician-diagnosed as having sinus headache: a randomized, double-blind, placebo-controlled study. Ishkanian G; Blumenthal H; Webster CJ; Richardson MS; Ames M Clin Ther; 2007 Jan; 29(1):99-109. PubMed ID: 17379050 [TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a 4-mg dose of subcutaneous sumatriptan for the treatment of acute migraine attacks in adults. Wendt J; Cady R; Singer R; Peters K; Webster C; Kori S; Byrd S Clin Ther; 2006 Apr; 28(4):517-26. PubMed ID: 16750463 [TBL] [Abstract][Full Text] [Related]
18. Early intervention in migraine with sumatriptan tablets 50 mg versus 100 mg: a pooled analysis of data from six clinical trials. Winner P; Landy S; Richardson M; Ames M Clin Ther; 2005 Nov; 27(11):1785-94. PubMed ID: 16368449 [TBL] [Abstract][Full Text] [Related]
19. Treatment of migraine attacks with subcutaneous sumatriptan: first placebo-controlled study. The Subcutaneous Sumatriptan International Study Group. Visser WH; Ferrari MD; Bayliss EM; Ludlow S; Pilgrim AJ Cephalalgia; 1992 Oct; 12(5):308-13. PubMed ID: 1330318 [TBL] [Abstract][Full Text] [Related]
20. Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device. The Sumatriptan Auto-Injector Study Group. Eur Neurol; 1991; 31(5):323-31. PubMed ID: 1653140 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]